Authorized purpose: CINA analyzes non-enhanced head CT and head CTA DICOM in parallel with standard interpretation to flag suspected intracranial hemorrhage and anterior-circulation large-vessel occlusion (distal ICA, MCA-M1 or proximal MCA-M2), issuing worklist and active notifications with informational previews for trained-radiologist triage; it does not diagnose or alter original images.
Clinical role
Parallel worklist prioritization and notification for suspected ICH or anterior-circulation LVO; not a diagnostic device or replacement for standard interpretation.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: LVO scope is limited to distal ICA, MCA-M1, or proximal MCA-M2 in the anterior circulation. Notifications and compressed previews are informational only, do not localize the finding, and require review of the full original images with other patient information.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: CINA analyzes non-enhanced head CT and head CTA DICOM in parallel with standard interpretation to flag suspected intracranial hemorrhage and anterior-circulation large-vessel occlusion (distal ICA, MCA-M1 or proximal MCA-M2), issuing worklist and active notifications with informational previews for trained-radiologist triage; it does not diagnose or alter original images.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: DICOM non-enhanced head CT for the ICH application and DICOM head CTA for the LVO application, subject to the recommended acquisition protocols.
Who uses it?Intended users: Hospital networks and trained radiologists; notified clinicians remain responsible for full-image review and professional judgment.
What does the software produce?Output: Active pop-up and passive worklist notifications identifying the suspected finding type, plus a small compressed unannotated grayscale preview marked not for diagnostic use; original images are not altered.
What is its most important limitation?Key limitation: LVO scope is limited to distal ICA, MCA-M1, or proximal MCA-M2 in the anterior circulation. Notifications and compressed previews are informational only, do not localize the finding, and require review of the full original images with other patient information.
Clinical takeaway. Clinical role: CINA analyzes non-enhanced head CT and head CTA DICOM in parallel with standard interpretation to flag suspected intracranial hemorrhage and anterior-circulation large-vessel occlusion (distal ICA, MCA-M1 or proximal MCA-M2), issuing worklist and active notifications with informational previews for trained-radiologist triage; it does not diagnose or alter original images.
Evidence takeaway. Evidence from the reviewed source record: K221716 contains two separately sized retrospective validation cohorts: 814 NCCT cases for ICH and 476 CTA cases for LVO. Results are reported per application and are not pooled.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
CINA analyzes non-enhanced head CT and head CTA DICOM in parallel with standard interpretation to flag suspected intracranial hemorrhage and anterior-circulation large-vessel occlusion (distal ICA, MCA-M1 or proximal MCA-M2), issuing worklist and active notifications with informational previews for trained-radiologist triage; it does not diagnose or alter original images.
Parallel worklist prioritization and notification for suspected ICH or anterior-circulation LVO; not a diagnostic device or replacement for standard interpretation.
Active pop-up and passive worklist notifications identifying the suspected finding type, plus a small compressed unannotated grayscale preview marked not for diagnostic use; original images are not altered.
LVO scope is limited to distal ICA, MCA-M1, or proximal MCA-M2 in the anterior circulation. Notifications and compressed previews are informational only, do not localize the finding, and require review of the full original images with other patient information.
K221716 contains two separately sized retrospective validation cohorts: 814 NCCT cases for ICH and 476 CTA cases for LVO. Results are reported per application and are not pooled.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K221716 contains two separately sized retrospective validation cohorts: 814 NCCT cases for ICH and 476 CTA cases for LVO. Results are reported per application and are not pooled.
DesignRetrospective blinded multicenter multinational standalone validation against concurrence of three US-board-certified neuroradiologists.
Population814 anonymized non-contrast head CT cases from three clinical sources (two US, one outside the US), including 255 ICH-positive cases and multiple scanner manufacturers.
Scopeexact submission
Tested versionCINA ICH/LVO triage configuration described in K221716
Samplen=814
Sites3
IndependenceSponsor or vendor study
K221716
Manufacturer-conducted FDA evidence; this is not an independent clinical-outcome study.
DesignRetrospective blinded multicenter multinational standalone validation against concurrence of three US-board-certified neuroradiologists.
Population476 anonymized head CTA cases from three clinical sources, including 188 anterior-circulation LVO-positive cases and multiple scanner manufacturers.
Scopeexact submission
Tested versionCINA ICH/LVO triage configuration described in K221716
Samplen=476
Sites3
IndependenceSponsor or vendor study
K221716
Manufacturer-conducted FDA evidence; this is not an independent clinical-outcome study.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-submission FDA recall query returned no native recall record for K221716. This limited query does not establish absence of recalls or other safety information and does not cover family or later-version records.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM non-enhanced head CT for the ICH application and DICOM head CTA for the LVO application, subject to the recommended acquisition protocols.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The on-premise CINA Platform exchanges DICOM with CT modalities, routers, and PACS, runs the ICH and LVO applications, and transfers result files for worklist prioritization. Local routing, identifiers, failure handling, and workstation behavior require acceptance testing.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: On-premise server or workstation using a standard off-the-shelf operating environment and an on-premise Worklist Application.
Scope: Exact FDA submission. This is the exact K221716 architecture; newer AVI Platform deployment claims are family context only.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Active pop-up and passive worklist notifications identifying the suspected finding type, plus a small compressed unannotated grayscale preview marked not for diagnostic use; original images are not altered.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Active pop-up and passive worklist notifications identifying the suspected finding type, plus a small compressed unannotated grayscale preview marked not for diagnostic use; original images are not altered.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The on-premise CINA Platform exchanges DICOM with CT modalities, routers, and PACS, runs the ICH and LVO applications, and transfers result files for worklist prioritization. Local routing, identifiers, failure handling, and workstation behavior require acceptance testing.
Avicenna.AI's cybersecurity page states ISO/IEC 27001 certification by SGS, IEC 81001-5-1, TLS 1.2+ in transit, encryption at rest, role-based access with least privilege, and a HIPAA business associate agreement for US customers. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
The exact submission describes DICOM exchange among CT, routers or PACS, an on-premise CINA Platform and Worklist Application, and result files returned for worklist prioritization.
Avicenna.AI's 2025 AVI announcement describes automated PACS/RIS integration, centralized orchestration, and DICOM, HL7, and FHIR support for the current platform hosting the CINA portfolio. It also describes de-identification, encryption, access controls, and auditable operations. These are family claims and do not establish the exact K221716 deployment or assurance scope.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-08Last searched
26Fields reviewed
12Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads
Stored exact-name candidate metadata was screened. The returned PubMed and trial records were unrelated to the CINA radiology product, so none was promoted; this is metadata triage, not a systematic literature review. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor press release, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-08 - Exact FDA submission
No public exact-version price, pricing unit, term, minimum, or implementation fee was established.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Avicenna CINA reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Avicenna's 2020-11-24 release describes NTAP eligibility for CINA Head (LVO triage); it does not tie that to this entry's clearance. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
The indication requires trained radiologists, but exact-version training and competency requirements were not established.
Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.